Research and development of antibody drugs

We are developing a technology (protein microarray) to detect a large number of antibodies* against invaders (viruses, bacteria, fungi, etc.) in the body in a single test. This test makes it easy to determine whether the antibodies present in the body react to the invaders on the protein microarray.
*Antibodies play an important role in eliminating invaders from the body.

In this case, we examined the reaction to a new coronavirus (SARS-CoV-2). We have also identified antibodies against SARS-CoV-2 in the blood and developing these antibodies as diagnostic agents and drugs for COVID-19. We are focusing on IgA, and are conducting research and development of antibody drugs using IgA.

IgA

IgA accounts for 10-15% of human serum immunoglobulins (antibody), and exists in two forms: a single basic Y-structure and a multimeric form consisting of multiple IgAs. IgA is found in serum, nasal secretions, saliva, breast milk, and intestinal fluids, and protects the body from invading pathogens. In addition, IgA contained in breast milk protects the digestive tract of newborns from pathogens.

Binding ability of IgA (HI001527) against SARS-CoV-2 used in hygiene products

Binds to most mutant spike proteins

Binds very strongly to Delta and Omicron strains

Binds very strongly to mutant spike proteins